Stocktoria

Nuvectis Pharma, Inc. NVCT

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2022-02-04

Nuvectis Pharma, Inc. statistics & valuation

Market cap$721.2M
P / B39.2×
Return on equity-143.6%
Return on capital-149.8%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
20212022202320242025
Operating margin (%)
20212022202320242025
Return on equity (%)
-134.20% -182.40% -195.60% -143.60% 20212022202320242025
Shares outstanding
4.5M 15.2M 17.4M 19.5M 25.7M 20212022202320242025
Net debt ($)
20212022202320242025
Share buybacks ($)
20212022202320242025
Return on assets (%)
-193.60% -93.50% -116.00% -102.10% -83.40% 20212022202320242025
Free cash flow margin (%)
20212022202320242025
Debt / equity (×)
20212022202320242025
EPS ($)
-$3.02 -$1.51 -$1.43 -$1.11 -$1.32 20212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021
Return on assets-83.4%-102.1%-116.0%-93.5%-193.6%
Return on equity-143.6%-195.6%-182.4%-134.2%117.1%
Current ratio2.382.092.753.302.41

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.